Myogenic tone and small artery remodelling: Insight into diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 361-369

  Khavandi, Kaivan ^a   Greenstein, Adam S ^a,b   Sonoyama, Kazuhiko ^a   Withers, Sarah ^a   Price, Anna ^a   Malik, Rayaz A ^a   Heagerty, Anthony M ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Diabetic nephropathy; Hypertension; Myogenic tone; Small artery remodelling; Target organ damage

Indexed keywords

AUTOREGULATION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; MEAN ARTERIAL PRESSURE; MUSCLE TONE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTERIES; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HOMEOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCLE, SMOOTH, VASCULAR; RENAL CIRCULATION; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 58449086169     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn583     Document Type: Review

References (92)

1. Molitch ME, DeFronzo RA, Franz MJ et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-S83
2. Warram JH, Gearin G, Laffel L et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7: 930-937
3. Mogensen CE, Poulsen PL. Epidemiology of microalbuminuria in diabetes and in the background population. Curr Opin Nephrol Hypertens 1994; 3: 248-256
4. Parving H-H, Chaturvedi N, Viberti G et al. Does microalbuminuria predict diabetic nephropathy? [comment]. Diabetes Care 2002; 25: 406-407
5. Rossi MCE, Nicolucci A, Pellegrini F et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008; 23: 1278-1284
6. Gaede P, Tarnow L, Vedel P et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784-2788
7. Perkins BA, Ficociello LH, Ostrander BE et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes [see comment]. J Am Soc Nephrol 2007; 18: 1353-1361
8. Perkins BA, Ficociello LH, Silva KH et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-2293
9. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(Suppl): S16-S23
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
11. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13(Suppl): I80-I93
12. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-388
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [see comment]. N Engl J Med 1993; 329: 977-986
14. Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study [see comment]. Arch Intern Med 2003; 163: 1555-1565
15. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982; 285: 685-688
16. Hostetter TH, Olson JL, Rennke HG et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-F93
17. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Renal Physiol 2007; 292: F1105-F1123
18. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32(Suppl 2): 64-78
19. Araki SI. Is glomerular filtration rate in children after 5 years of type 1 diabetes associated with development of albuminuria? Nat Clin Pract Nephrol 2006; 2: 242-243
20. Nowack R, Raum E, Blum W et al. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992; 20: 342-347
21. Mogensen CE, Andersen MJ. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 1975; 11: 221-224
22. Parving HH, Kastrup H, Smidt UM et al. Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1984; 27: 547-552
23. Christensen PK, Hansen HP, Parving H-H. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369-1374
24. Anderson S. Relevance of single nephron studies to human glomerular function. Kidney Int 1994; 45: 384-389
25. Girach A, Vignati L. Diabetic microvascular complications - can the presence of one predict the development of another? J Diabetes Complications 2006; 20: 228-237
26. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature [see comment]. Arch Intern Med 1997; 157: 1413-1418
27. Martinez-Lemus LA, Crow T, Davis MJ et al. Alphavbeta3- and alpha5beta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol Heart Circ Physiol 2005; 289: H322-H329
28. Osol G, Brekke JF, McElroy-Yaggy K et al. Myogenic tone, reactivity, and forced dilatation: a three-phase model of in vitro arterial myogenic behavior. Am J Physiol Heart Circ Physiol 2002; 283: H2260-H2267
29. Hill MA, Davis MJ, Meininger GA et al. Arteriolar myogenic signalling mechanisms: implications for local vascular function. Clin Hemorheol Microcirc 2006; 34: 67-79
30. Aalkjaer C, Heagerty AM, Petersen KK et al. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation - contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987; 61: 181-186
31. Tahvanainen A, Taurio J, Maki-Jouppi J et al. Increased wall tension in response to vasoconstrictors in isolated mesenteric arterial rings from patients with high blood pressure. Basic Clin Pharmacol Toxicol 2006; 99: 440-449
32. Jenkins JT, Boyle JJ, McKay IC et al. Vascular remodelling in intramyocardial resistance vessels in hypertensive human cardiac transplant recipients. Heart 1997; 77: 353-356
33. Wallis SJ, Firth J, Dunn WR. Pressure-induced myogenic responses in human isolated cerebral resistance arteries. Stroke 1996; 27: 2287-2290; discussion 2291
34. Rizzoni D, Porteri E, Piccoli A et al. Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998; 32: 305-310
35. Bund SJ, Oldham AA, Allott CP et al. Effect of one-kidney, one clip hypertension on the structure and function of porcine intramyocardial small arteries. J Hypertens 1995; 13: 535-541
36. Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. In: Williams B (ed). Hypertension in Diabetes. London and New York: Martin Dunitz Publisher. 2003, 99-111
37. Wong TY, Klein R, Couper DJ et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358: 1134-1140
38. Klein R, Klein BE, Moss SE et al. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2004; 122: 76-83
39. Wong TY, Shankar A, Klein R et al. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes 2004; 53: 179-184
40. Izzard AS, Graham D, Burnham MP et al. Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2003; 285: H1489-H1494
41. Schofield I, Malik R, Izzard A et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106: 3037-3043
42. Blum M, Pils C, Muller UA et al. The myogenic response of retinal arterioles in diabetic retinopathy. Ophthalmologe 2006; 103: 209-213
43. Rassam SM, Patel V, Kohner EM. The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 1995; 80: 53-68
44. Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 2007; 73: 198-205
45. Ito I, Jarajapu YP, Guberski DL et al. Myogenic tone and reactivity of rat ophthalmic artery in acute exposure to high glucose and in a type II diabetic model. Invest Ophthalmol Vis Sci 2006; 47: 683-692
46. Vettoretti S, Ochodnicky P, Buikema H et al. Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats [see comment]. J Hypertens 2006; 24: 2215-2223
47. van Dokkum RP, Sun CW, Provoost AP et al. Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol 1999; 276: R855-R863
48. Churchill PC, Churchill MC, Bidani AK et al. Genetic susceptibility to hypertension-induced renal damage in the rat. Evidence based on kidney-specific genome transfer. J Clin Invest 1997; 100: 1373-1382
49. Wang X, Ajikobi DO, Salevsky FC et al. Impaired myogenic autoregulation in kidneys of Brown Norway rats. Am J Physiol Renal Physiol 2000; 278: F962-F969
50. Hayashi K, Epstein M, Loutzenhiser R et al. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2: 1578-1586
51. Azar S, Johnson MA, Iwai J et al. Single-nephron dynamics in "postsalt" rats with chronic hypertension. J Lab Clin Med 1978; 91: 156-166
52. Raij L, Azar S, Keane WF. Role of hypertension in progressive glomerular immune injury. Hypertension 1985; 7: 398-404
53. Hayashi K, Epstein M, Loutzenhiser R. Pressure-induced vasoconstriction of renal microvessels in normotensive and hypertensive rats. Studies in the isolated perfused hydronephrotic kidney. Circ Res 1989; 65: 1475-1484
54. Hayashi K, Epstein M, Loutzenhiser R. Determinants of renal actions of atrial natriuretic peptide. Lack of effect of atrial natriuretic peptide on pressure-induced vasoconstriction. Circ Res 1990; 67: 1-10
55. Zatz R, Meyer TW, Rennke HG et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963-5967
56. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930
57. Scholey JW, Meyer TW. Control of glomerular hypertension by insulin administration in diabetic rats. J Clin Invest 1989; 83: 1384-1389
58. Bell TD, DiBona GF, Wang Y et al. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol 2006; 17: 2184-2192
59. Kriz W, Hosser H, Hahnel B et al. Development of vascular pole-associated glomerulosclerosis in the fawn-hooded rat. J Am Soc Nephrol 1998; 9: 381-396
60. Kuijpers MH, Provoost AP, de Jong W. Development of hypertension and proteinuria with age in fawn-hooded rats. Clin Exp Pharmacol Physiol 1986; 13: 201-209
61. Dworkin LD, Feiner HD. Glomerular injury in uninephrectomized spontaneously hypertensive rats. A consequence of glomerular capillary hypertension. J Clin Invest 1986; 77: 797-809
62. Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol 1979; 236: F246-F251
63. Inscho EW, Cook AK, Imig JD et al. Physiological role for P2x1 receptors in renal microvascular autoregulatory behavior. J Clin Invest 2003; 112: 1895-1905
64. Loutzenhiser R, Griffin K, Williamson G et al. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1153-R1167
65. Verseput GH, Braam B, Provoost AP et al. Tubuloglomerular feedback and prolonged ACE-inhibitor treatment in the hypertensive fawn-hooded rat. Nephrol Dial Transplant 1998; 13: 893-899
66. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005; 6: 56-68
67. Intengan HD, Thibault G, Li JS et al. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100: 2267-2675
68. Bakker EN, Buus CL, VanBavel E et al. Activation of resistance arteries with endothelin-1: from vasoconstriction to functional adaptation and remodeling. J Vasc Res 2004; 41: 174-182
69. Heerkens EH, Izzard AS, Heagerty AM. Integrins, vascular remodeling, and hypertension. Hypertension 2007; 49: 1-4
70. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-318
71. Mercurius KO, Morla AO. Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly. Circ Res 1998; 82: 548-556
72. Gnudi L, Viberti G, Raij L et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003; 42: 19-24
73. Heerkens EH, Shaw L, Ryding A et al. AlphaV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension. Hypertension 2006; 47: 281-287
74. Thybo NK, Korsgaard N, Mulvany MJ. Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J Hypertens 1992; 10: 1191-1196
75. Stephens RH, McElduff P, Heald AH et al. Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes 2005; 54: 3547-3553
76. Drummond HA, Jernigan NL, Grifoni SC. Sensing tension: epithelial sodium channel/acid-sensing ion channel proteins in cardiovascular homeostasis. Hypertension 2008; 51: 1265-1271
77. Jernigan NL, Drummond HA. Vascular ENaC proteins are required for renal myogenic constriction. Am J Physiol Renal Physiol 2005; 289: F891-F901
78. Gannon KP, Vanlandingham LG, Jernigan NL et al. Impaired pressure-induced constriction in mouse middle cerebral arteries of ASIC2 knockout mice. Am J Physiol Heart Circ Physiol 2008; 294: H1793-H1803
79. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comment]. Lancet 1998; 351: 1755-1762
80. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [erratum appears in J Hypertens. August 2007; 25(8):1749]. J Hypertens 2007; 25: 1105-1187
81. Schmieder RE. Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol 1994; 24(Suppl 2): S55-S64
82. The EUCLID Study Group Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria [see comment]. Lancet 1997; 349: 1787-1792
83. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [see comment] [erratum appears in 2000 May 4; 342(18):1376]. N Engl J Med 2000; 342: 145-153
84. Schmitz A, Christensen T, Taagehoej Jensen F. Glomerular filtration rate and kidney volume in normoalbuminuric non-insulin-dependent diabetics - lack of glomerular hyperfiltration and renal hypertrophy in uncomplicated NIDDM. Scand J Clin Lab Invest 1989; 49: 103-108
85. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [see comment]. JAMA 2001; 286: 421-426
86. Tapp RJ, Shaw JE, Zimmet PZ et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004; 44: 792-798
87. Tapp RJ, Shaw JE, Harper CA et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003; 26: 1731-1737
88. Thybo NK, Stephens N, Cooper A et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25: 474-481
89. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [see comment]. N Engl J Med 2001; 345: 851-860
90. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. [see comment]. Lancet 1997; 349: 1857-1863
91. Lewis EJ, Hunsicker LG, Bain RP et al. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
92. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456